1 Market Overview of Targeted Drug VEGF Inhibitors for NSCLC 1.1 Targeted Drug VEGF Inhibitors for NSCLC Market Overview 1.1.1 Targeted Drug VEGF Inhibitors for NSCLC Product Scope 1.1.2 Targeted Drug VEGF Inhibitors for NSCLC Market Status and Outlook 1.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Overview by Region 2016 VS 2021VS 2027 1.3 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2016-2027) 1.4 Global Targeted Drug VEGF Inhibitors for NSCLC Historic Market Size by Region (2016-2021) 1.5 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Region (2022-2027) 1.6 Key Regions, Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) 1.6.1 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) 1.6.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) 1.6.3 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) 1.6.4 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) 1.6.5 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) 2 Targeted Drug VEGF Inhibitors for NSCLC Market Overview by Type 2.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type: 2016 VS 2021 VS 2027 2.2 Global Targeted Drug VEGF Inhibitors for NSCLC Historic Market Size by Type (2016-2021) 2.3 Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Type (2022-2027) 2.4 Bevacizumab 2.5 Other 3 Targeted Drug VEGF Inhibitors for NSCLC Market Overview by Application 3.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application: 2016 VS 2021 VS 2027 3.2 Global Targeted Drug VEGF Inhibitors for NSCLC Historic Market Size by Application (2016-2021) 3.3 Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Application (2022-2027) 3.4 Squamous Cell Carcinoma of NSCLC 3.5 Adenocarcinoma of NSCLC 3.6 Large Cell Carcinoma of NSCLC 4 Targeted Drug VEGF Inhibitors for NSCLC Competition Analysis by Players 4.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Players (2016-2021) 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Targeted Drug VEGF Inhibitors for NSCLC as of 2020) 4.3 Date of Key Players Enter into Targeted Drug VEGF Inhibitors for NSCLC Market 4.4 Global Top Players Targeted Drug VEGF Inhibitors for NSCLC Headquarters and Area Served 4.5 Key Players Targeted Drug VEGF Inhibitors for NSCLC Product Solution and Service 4.6 Competitive Status 4.6.1 Targeted Drug VEGF Inhibitors for NSCLC Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data 5.1 Roche 5.1.1 Roche Profile 5.1.2 Roche Main Business 5.1.3 Roche Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions 5.1.4 Roche Targeted Drug VEGF Inhibitors for NSCLC Revenue (US$ Million) & (2016-2021) 5.1.5 Roche Recent Developments 5.2 Pfizer 5.2.1 Pfizer Profile 5.2.2 Pfizer Main Business 5.2.3 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions 5.2.4 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Revenue (US$ Million) & (2016-2021) 5.2.5 Pfizer Recent Developments 5.3 Allergan 5.5.1 Allergan Profile 5.3.2 Allergan Main Business 5.3.3 Allergan Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions 5.3.4 Allergan Targeted Drug VEGF Inhibitors for NSCLC Revenue (US$ Million) & (2016-2021) 5.3.5 Amgen Recent Developments 5.4 Amgen 5.4.1 Amgen Profile 5.4.2 Amgen Main Business 5.4.3 Amgen Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions 5.4.4 Amgen Targeted Drug VEGF Inhibitors for NSCLC Revenue (US$ Million) & (2016-2021) 5.4.5 Amgen Recent Developments 5.5 Biocon 5.5.1 Biocon Profile 5.5.2 Biocon Main Business 5.5.3 Biocon Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions 5.5.4 Biocon Targeted Drug VEGF Inhibitors for NSCLC Revenue (US$ Million) & (2016-2021) 5.5.5 Biocon Recent Developments 5.6 Reliance Lifesciences 5.6.1 Reliance Lifesciences Profile 5.6.2 Reliance Lifesciences Main Business 5.6.3 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions 5.6.4 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Revenue (US$ Million) & (2016-2021) 5.6.5 Reliance Lifesciences Recent Developments 5.7 Beaconpharma 5.7.1 Beaconpharma Profile 5.7.2 Beaconpharma Main Business 5.7.3 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions 5.7.4 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Revenue (US$ Million) & (2016-2021) 5.7.5 Beaconpharma Recent Developments 5.8 Celgene Corporation 5.8.1 Celgene Corporation Profile 5.8.2 Celgene Corporation Main Business 5.8.3 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions 5.8.4 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Revenue (US$ Million) & (2016-2021) 5.8.5 Celgene Corporation Recent Developments 5.9 Fujifilm Kyowa Kirin Biologics 5.9.1 Fujifilm Kyowa Kirin Biologics Profile 5.9.2 Fujifilm Kyowa Kirin Biologics Main Business 5.9.3 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions 5.9.4 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Revenue (US$ Million) & (2016-2021) 5.9.5 Fujifilm Kyowa Kirin Biologics Recent Developments 5.10 Hetero Drugs 5.10.1 Hetero Drugs Profile 5.10.2 Hetero Drugs Main Business 5.10.3 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions 5.10.4 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Revenue (US$ Million) & (2016-2021) 5.10.5 Hetero Drugs Recent Developments 6 North America 6.1 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2027) 6.2 United States 6.3 Canada 7 Europe 7.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2027) 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2016-2027) 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2027) 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2027) 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 Targeted Drug VEGF Inhibitors for NSCLC Market Dynamics 11.1 Targeted Drug VEGF Inhibitors for NSCLC Industry Trends 11.2 Targeted Drug VEGF Inhibitors for NSCLC Market Drivers 11.3 Targeted Drug VEGF Inhibitors for NSCLC Market Challenges 11.4 Targeted Drug VEGF Inhibitors for NSCLC Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List

List of Tables Table 1. Global Market Targeted Drug VEGF Inhibitors for NSCLC Market Size (US$ Million) Comparison by Region 2016 VS 2021 VS 2027 Table 2. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2016-2021) & (US$ Million) Table 3. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Region (2016-2021) Table 4. Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Region (2022-2027) & (US$ Million) Table 5. Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size Share by Region (2022-2027) Table 6. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (US$ Million) by Type: 2016 VS 2021 VS 2027 Table 7. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2021) & (US$ Million) Table 8. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Type (2016-2021) Table 9. Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Type (2022-2027) & (US$ Million) Table 10. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Type (2022-2027) Table 11. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (US$ Million) by Application: 2016 VS 2021 VS 2027 Table 12. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2021) & (US$ Million) Table 13. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Application (2016-2021) Table 14. Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Application (2022-2027) & (US$ Million) Table 15. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Application (2022-2027) Table 16. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue (US$ Million) by Players (2016-2021) Table 17. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Players (2016-2021) Table 18. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Targeted Drug VEGF Inhibitors for NSCLC as of 2020) Table 19. Date of Key Manufacturers Enter into Targeted Drug VEGF Inhibitors for NSCLC Market Table 20. Global Targeted Drug VEGF Inhibitors for NSCLC Top Players Headquarters and Area Served Table 21. Targeted Drug VEGF Inhibitors for NSCLC Product Solution and Service Table 22. Global Targeted Drug VEGF Inhibitors for NSCLC Players Market Concentration Ratio (CR5 and HHI) Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Roche Basic Information List Table 25. Roche Description and Business Overview Table 26. Roche Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions Table 27. Revenue (US$ Million) in Targeted Drug VEGF Inhibitors for NSCLC Business of Roche (2016-2021) Table 28. Roche Recent Developments Table 29. Pfizer Basic Information List Table 30. Pfizer Description and Business Overview Table 31. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions Table 32. Revenue (US$ Million) in Targeted Drug VEGF Inhibitors for NSCLC Business of Pfizer (2016-2021) Table 33. Pfizer Recent Developments Table 34. Allergan Basic Information List Table 35. Allergan Description and Business Overview Table 36. Allergan Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions Table 37. Revenue (US$ Million) in Targeted Drug VEGF Inhibitors for NSCLC Business of Allergan (2016-2021) Table 38. Allergan Recent Developments Table 39. Amgen Basic Information List Table 40. Amgen Description and Business Overview Table 41. Amgen Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions Table 42. Revenue (US$ Million) in Targeted Drug VEGF Inhibitors for NSCLC Business of Amgen (2016-2021) Table 43. Amgen Recent Developments Table 44. Biocon Basic Information List Table 45. Biocon Description and Business Overview Table 46. Biocon Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions Table 47. Revenue (US$ Million) in Targeted Drug VEGF Inhibitors for NSCLC Business of Biocon (2016-2021) Table 48. Biocon Recent Developments Table 49. Reliance Lifesciences Basic Information List Table 50. Reliance Lifesciences Description and Business Overview Table 51. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions Table 52. Revenue (US$ Million) in Targeted Drug VEGF Inhibitors for NSCLC Business of Reliance Lifesciences (2016-2021) Table 53. Reliance Lifesciences Recent Developments Table 54. Beaconpharma Basic Information List Table 55. Beaconpharma Description and Business Overview Table 56. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions Table 57. Revenue (US$ Million) in Targeted Drug VEGF Inhibitors for NSCLC Business of Beaconpharma (2016-2021) Table 58. Beaconpharma Recent Developments Table 59. Celgene Corporation Basic Information List Table 60. Celgene Corporation Description and Business Overview Table 61. Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions Table 62. Revenue (US$ Million) in Targeted Drug VEGF Inhibitors for NSCLC Business of Celgene Corporation (2016-2021) Table 63. Celgene Corporation Recent Developments Table 64. Fujifilm Kyowa Kirin Biologics Basic Information List Table 65. Fujifilm Kyowa Kirin Biologics Description and Business Overview Table 66. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions Table 67. Revenue (US$ Million) in Targeted Drug VEGF Inhibitors for NSCLC Business of Fujifilm Kyowa Kirin Biologics (2016-2021) Table 68. Fujifilm Kyowa Kirin Biologics Recent Developments Table 69. Hetero Drugs Basic Information List Table 70. Hetero Drugs Description and Business Overview Table 71. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Products, Services and Solutions Table 72. Revenue (US$ Million) in Targeted Drug VEGF Inhibitors for NSCLC Business of Hetero Drugs (2016-2021) Table 73. Hetero Drugs Recent Developments Table 74. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2021) & (US$ Million) Table 75. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2022-2027) & (US$ Million) Table 76. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2021) & (US$ Million) Table 77. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2022-2027) & (US$ Million) Table 78. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2016-2021) & (US$ Million) Table 79. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2022-2027) & (US$ Million) Table 80. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Share by Region (2016-2021) Table 81. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Share by Region (2022-2027) Table 82. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2021) & (US$ Million) Table 83. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2022-2027) & (US$ Million) Table 84. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Players (2016-2021) & (US$ Million) Table 85. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2022-2027) & (US$ Million) Table 86. Targeted Drug VEGF Inhibitors for NSCLC Market Trends Table 87. Targeted Drug VEGF Inhibitors for NSCLC Market Drivers Table 88. Targeted Drug VEGF Inhibitors for NSCLC Market Challenges Table 89. Targeted Drug VEGF Inhibitors for NSCLC Market Restraints Table 90. Research Programs/Design for This Report Table 91. Key Data Information from Secondary Sources Table 92. Key Data Information from Primary Sources List of Figures Figure 1. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Year-over-Year 2016-2027 & (US$ Million) Figure 2. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 3. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions: 2021 VS 2027 Figure 4. Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size Share by Region (2022-2027) Figure 5. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size (US$ Million) Growth Rate (2016-2027) Figure 6. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size (US$ Million) and Growth Rate (2016-2027) Figure 7. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size (US$ Million) and Growth Rate (2016-2027) Figure 8. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size (US$ Million) and Growth Rate (2016-2027) Figure 9. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size (US$ Million) and Growth Rate (2016-2027) Figure 10. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Type in 2021 & 2027 Figure 11. Bevacizumab Market Size (US$ Million) YoY Growth (2016-2027) Figure 12. Other Market Size (US$ Million) YoY Growth (2016-2027) Figure 13. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Application in 2021 & 2027 Figure 14. Squamous Cell Carcinoma of NSCLC Market Size (US$ Million) YoY Growth (2016-2027) Figure 15. Adenocarcinoma of NSCLC Market Size (US$ Million) YoY Growth (2016-2027) Figure 16. Large Cell Carcinoma of NSCLC Market Size (US$ Million) YoY Growth (2016-2027) Figure 17. Targeted Drug VEGF Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020 Figure 18. Global Top 5 and Top 10 Players Targeted Drug VEGF Inhibitors for NSCLC Market Share in 2020 Figure 19. North America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Country (2016-2027) Figure 20. United States Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 21. Canada Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 22. Germany Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 23. France Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 24. U.K. Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 25. Italy Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 26. Russia Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 27. Nordic Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 28. Rest of Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 29. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Share by Region (2016-2027) Figure 30. China Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 31. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 32. South Korea Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 33. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 34. India Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 35. Australia Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 36. Rest of Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 37. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Country (2016-2027) Figure 38. Mexico Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 39. Brazil Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 40. Rest of Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 41. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Share by Country (2016-2027) Figure 42. Turkey Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 43. Saudi Arabia Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 44. UAE Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 45. Rest of Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027) & (US$ Million) Figure 46. Bottom-up and Top-down Approaches for This Report Figure 47. Data Triangulation

Roche Pfizer Allergan Amgen Biocon Reliance Lifesciences Beaconpharma Celgene Corporation Fujifilm Kyowa Kirin Biologics Hetero Drugs